Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cladribine
Drug ID BADD_D00479
Description An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Indications and Usage For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
Marketing Status approved; investigational
ATC Code L01BB04; L04AA40
DrugBank ID DB00242
KEGG ID D01370
MeSH ID D017338
PubChem ID 20279
TTD Drug ID D05GJW
NDC Product Code 42658-010; 12502-5406; 0143-9871; 44087-4000; 54893-0115; 76055-0051; 63323-140; 59605-3006; 65129-1260; 76055-0052; 12502-4912; 58623-0037
UNII 47M74X9YT5
Synonyms Cladribine | 2-Chlorodeoxyadenosine | 2-Chloro-2'-deoxyadenosine | 2'-Deoxy-2-chloroadenosine | Leustatin
Chemical Information
Molecular Formula C10H12ClN5O3
CAS Registry Number 4291-63-8
SMILES C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rales22.12.01.011--Not Available
Rash23.03.13.0010.004694%Not Available
Rash erythematous23.03.13.0290.000596%Not Available
Rash macular23.03.13.003--Not Available
Rash maculo-papular23.03.13.0040.000459%
Rash pruritic23.03.13.0300.001300%Not Available
Renal disorder20.01.02.0020.000336%Not Available
Renal failure20.01.03.005--Not Available
Retinal tear12.01.04.014; 06.09.03.010--
Rheumatoid arthritis15.01.03.001; 10.04.06.0010.000153%Not Available
Seizure17.12.03.001--
Sensory disturbance17.02.07.0060.000229%Not Available
Sepsis11.01.11.003--
Septic shock11.01.11.004; 24.06.02.011--Not Available
Skin cancer23.08.02.002; 16.03.02.0020.000382%Not Available
Skin disorder23.03.03.007--Not Available
Skin infection23.11.04.007; 11.01.12.003--
Skin lesion23.03.03.0100.000229%Not Available
Skin necrosis23.03.03.0110.000856%Not Available
Skin reaction23.03.03.013; 10.01.03.0190.000336%Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.000413%Not Available
Squamous cell carcinoma16.16.01.0020.000153%Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Stress19.06.02.004--Not Available
Suicidal ideation19.12.01.003--
Swelling08.01.03.015--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Therapeutic response decreased08.06.01.016--Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 12 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene